Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?
| Autor: | Sini-Marja Sjöblom, Timo Sane, Risto Pelkonen, P I Salmela, Heikki Järvinen, Matti Välimäki |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Pathology Interferon therapy Computed tomography Carcinoid Tumor Interferon alpha-2 Gastroenterology Urinary levels Interferon Internal medicine medicine Humans Aged Leukopenia medicine.diagnostic_test Human leukocyte interferon business.industry Remission Induction Metastatic carcinoid tumor Interferon-alpha Hydroxyindoleacetic Acid Middle Aged medicine.disease Recombinant Proteins 3. Good health Oncology Interferon Type I Female medicine.symptom business Tomography X-Ray Computed Carcinoid syndrome medicine.drug |
| Zdroj: | Cancer. 67(3) |
| ISSN: | 0008-543X |
| Popis: | Eight patients with metastatic carcinoid tumor, seven of whom had symptoms of the carcinoid syndrome, were treated with either human leukocyte interferon (seven patients) or recombinant alpha-interferon (IFN alpha-2b) (one patient) at doses of 4.5 to 21 x 10(6) IU weekly for 1 to 21 (mean, 8.5) months. Tumor regression on computed tomography (CT) scan was found in one patient, the CT findings remained unchanged in three, and the tumor progressed in four patients. A clearcut and continuing decrease in urinary levels of 5-hydroxyindoleacetic acid (5-HIAA) was observed in one patient and a transient one in four patients. The symptoms improved in only two of seven patients. Four patients had leukopenia develop, which was circumvented by reducing the dose. The authors conclude that interferon therapy of the carcinoid tumor is not as successful as has been suggested in previous reports. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text